iCAD

iCAD, Inc. is a medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment is composed of radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iCAD implements strategic changes to drive profitability and growth

iCAD is strategically focusing on cost reduction, revenue diversification, and transitioning to a subscription model to drive profitability by 2024. Leveraging partnerships with Google and other organizations, the company aims to expand its market reach and enhance operational efficiency. Despite facing competition and market challenges, iCAD remains optimistic about its growth prospects.

iCAD reports Q1 revenue decline, eyes growth in AI healthcare

iCAD faced revenue decline in Q1 2023, with a focus on detection and therapy segments, while maintaining a strong gross profit margin.
The company's Xoft technology and partnership with Google Health present promising growth opportunities in the AI healthcare space.
Challenges include lower-than-expected Xoft business revenue, competition in AI software, and delays in partnership agreements.

iCAD reports Q2 revenue decline, eyes growth through strategic partnerships

iCAD's Q2 2023 Earnings Call showcased a revenue decline but highlighted progress in the detection segment and strategic partnerships. The company aims for recurring revenue through subscription deals and is focused on cost reductions and stability. Opportunities lie in expanding partnerships and securing growth with healthcare facilities globally.

iCAD reports improved operational metrics and strategic partnerships in Q3 '23

iCAD's Q3 '23 earnings call highlighted operational improvements, strategic partnerships, and a focus on growth initiatives. Despite a revenue decline and operating loss, the company has made progress in reducing EBITDA loss and cash burn. iCAD's financial position remains stable with sufficient resources for planned operations.

iCAD reports improved financials and strategic growth initiatives for 2024

iCAD's financial performance showed improvements in revenue, EBITDA loss, and operational efficiency, driven by strategic initiatives.
The company's focus on AI solutions, geographic expansion, and recurring revenue model positions it for future growth.
While facing challenges in market adoption and OpEx increases, iCAD has opportunities to capitalize on market growth and new product developments.

iCAD reports revenue growth and strategic expansion in Q1 2024

iCAD's Q1 2024 performance reflects positive momentum with revenue growth, improved profitability metrics, and strategic advancements
The company's focus on innovation, market expansion, and cost control positions them well for future growth and market leadership
While challenges like revenue seasonality and competitive pressures exist, iCAD's strengths in product development and global expansion offer opportunities for sustained growth
Overall, iCAD's Q1 2024 earnings call underscores a promising outlook with a strong foundation for continued success in the medical technology sector

iCAD reports 4% revenue growth, FDA clearance boosts cancer detection

iCAD's Q3 performance reflects growth in revenue and strategic partnerships, underpinned by AI technology.
While facing challenges in service revenue and net loss, the company's global expansion and product advancements signal resilience.
Opportunities lie in market expansion, innovation in breast cancer detection, and transitioning to a recurring revenue model.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

NASHUA, N.H., Feb. 14, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, February 28.

iCAD to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28

Leading-edge breast cancer detection platform meets stringent U.S. government security thresholds required for use across military healthcare facilities Leading-edge breast cancer detection platform meets stringent U.S. government security thresholds required for use across military healthcare facilities

iCAD's Breast AI Platform Earns U.S. Department of Defense Authorization to Operate

Dana Brown and Timothy Norris Irish offer extensive experience in technology, women's breast health and unique global perspectives Dana Brown and Timothy Norris Irish offer extensive experience in technology, women's breast health and unique global perspectives

iCAD Announces the Appointment of New Members to its Board of Directors

AYRO

Bionano Genomics

Quantum Computing

Safe-T Group Ltd - ADR

Electrameccanica

These cheap stocks under $10 are poised to rally in the new, more friendly macro environment that's in place as 2022 unfolds. The post 7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now appeared first on InvestorPlace.

7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now

Company's President and incoming CEO to participate in a panel discussion titled “Med Tech / Digital Tools: What's the Mindset for 2022?” on January 5, 2022 at 2:00 pm ET Company's President and incoming CEO to participate in a panel discussion titled “Med Tech / Digital Tools: What's the Mindset for 2022?” on January 5, 2022 at 2:00 pm ET

iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event

Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor

First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States

NASHUA, N.H., Dec. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens, President and incoming Chief Executive Officer, will present a corporate overview at Oppenheimer's Imagine AI + Healthcare Investor Summit being hosted by Oppenheimer in partnership with the Alliance for AI in Healthcare (AAIH).

iCAD to Participate at the Imagine AI + Healthcare Investor Summit

Stacey Stevens Appointed as President and CEO and will Join the Board of Directors in 2022, Michael Klein to remain Chairman of iCAD Board Stacey Stevens Appointed as President and CEO and will Join the Board of Directors in 2022, Michael Klein to remain Chairman of iCAD Board

iCAD Announces CEO Transition

NASHUA, N.H., Nov. 11, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will participate in the 12th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 16, 2021, starting at 9:00 AM ET.

iCAD to Participate in the 12th Annual Craig-Hallum Alpha Select Conference

iCAD, Inc. (ICAD) CEO Michael Klein on Q3 2021 Results - Earnings Call Transcript

Icad (ICAD) delivered earnings and revenue surprises of 0.00% and -0.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Icad (ICAD) Reports Q3 Loss, Misses Revenue Estimates

Icad (ICAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Icad (ICAD) Q3 Earnings Expected to Decline

First Majestic Silver

Activision Blizzard

Lam Research

Micron Technology

Palantir Technologies

Sierra Wireless

Market volatility has provided investors with some prime opportunities. These high-quality stocks to buy have very attractive price points.

7 Best Stocks to Buy on the Dip in October

Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

iCAD Unveils Next Generation Technologies at Journées Francophones de Radiologie (October 8-11, Paris, France)

Latest generation of ProFound AI Risk offers greater accuracy and ethnically inclusive precision screening

iCAD Launches Revolutionary Short-term Personalized Risk Assessment Solution for 3D Mammography

Leading experts to discuss novel AI technology helping them overcome pandemic-related challenges including substantial mammography backlog Leading experts to discuss novel AI technology helping them overcome pandemic-related challenges including substantial mammography backlog

iCAD to Host Educational Roundtable to Help Clinicians and Facilities Recover from COVID-19 Impact

Schrodinger 

Upstart Holdings

Companies with focused AI technologies appear to be doing better than firms with AI based on general data. Here are four AI stocks to buy.

4 Specialized AI Stocks to Buy for the Boom

iCAD, Inc. (ICAD) CEO Michael Klein on Q2 2021 Results - Earnings Call Transcript

iCAD Inc (NASDAQ: ICAD) reported Q2 adjusted EPS loss of $(0.11) slightly better than $(0.12) a year ago, but missing the consensus of $(0.07). Sales increased 41% Y/Y to $7.8 million, missing the wall street estimate of $9.15 million.

iCAD Q2 Earnings Lag Street Estimates As Sales Impacted By Longer Enterprise Sales Cycles

Conference Call Today at 4:30 PM ET Conference Call Today at 4:30 PM ET

iCAD Reports Financial Results for the Quarter Ended June 30, 2021

NASHUA, N.H., Aug. 02, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, and Stacey Stevens, President, will participate in a fireside chat at the Guggenheim MedTech Disruptors Summit, taking place virtually on August 9-10, 2021.

iCAD to Participate in the Guggenheim MedTech Disruptors Summit

Icad (ICAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NASHUA, N.H., July 22, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, August 5.

iCAD to Report Second Quarter 2021 Financial Results on Thursday, August 5

iCAD's third generation artificial intelligence solution for 3D mammography offers considerable improvement in algorithm specificity performance and faster processing compared to previous generations iCAD's third generation artificial intelligence solution for 3D mammography offers considerable improvement in algorithm specificity performance and faster processing compared to previous generations

iCAD's ProFound AI for Digital Breast Tomosynthesis Version 3.0 Receives CE Mark Approval

Agreement will expand access to ProFound AI and ProFound AI Risk to more facilities and imaging centers worldwide Agreement will expand access to ProFound AI and ProFound AI Risk to more facilities and imaging centers worldwide

News for iCAD Stock (ICAD)